Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines | Practical Law

Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines | Practical Law

On 19 June 2013, the European Commission announced that it has imposed a fine of EUR93.8 million on Danish pharmaceutical company Lundbeck and fines totalling EUR52.2 million on several producers of generic medicines for preventing market entry of a generic antidepressant medicine in breach of Article 101 of the TFEU.

Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines

by Practical Law Competition
Law stated as at 19 Jun 2013 • European Union
On 19 June 2013, the European Commission announced that it has imposed a fine of EUR93.8 million on Danish pharmaceutical company Lundbeck and fines totalling EUR52.2 million on several producers of generic medicines for preventing market entry of a generic antidepressant medicine in breach of Article 101 of the TFEU.